Alteration of treatment choices and the visual prognosis for diabetic macular edema in the era of anti-VEGF drugs: Analysis of the STREAT-DME 2 study
Masahiko Shimura,Takao Hirano,Eiko Tsuiki,Yoshihiro Takamura,Yuki Morizane,Kunihiko Akiyama,Kaori Yamamoto,Taichi Hikichi,Takashi Koto,Takamasa Kinoshita,Sentaro Kusuhara,Shigeo Yoshida,Shin-Ichi Sakamoto,Kazuhiro Kimura,Masahiko Sugimoto,Teruyo Kida,Yoshinori Mitamura,Yoko Takatsuna,Noriaki Washio,Rie Osaka,Tetsuki Ueda,Akira Minamoto,Jiro Kogo,Fumiki Okamoto,Hiroshi Enaida,Yoshihito Sakanishi,Taiji Nagaoka,Fumi Gomi,Mariko Sasaki,Hiroto Terasaki,Tsuyoshi Iwase,Tomoaki Tatsumi,Kosuke Nishi,Kei Shinoda,Shunichiro Ueda,Tomoko Ueda-Consolvo,Hiroyuki Nakashizuka,Toshinori Murata,Shigehiko Kitano,Taiji Sakamoto,J-CREST STREAT-DME 2 Study Group
DOI: https://doi.org/10.1097/IAE.0000000000004301
2024-10-15
Retina
Abstract:Purpose: To assess the real-world outcome of best-corrected visual acuity (BCVA) following 2-year intervention for treatment-naïve diabetic macular edema (DME) since the approval of anti-vascular endothelial growth factor (VEGF) therapy. Methods: A total of 1,780 treatment-naïve eyes with DME for which intervention was initiated between 2015 and 2019, and which were followed for 2 years, were extracted from the longitudinal medical records of 37 retinal disease institutions in Japan. Interventions included anti-VEGF therapy, topical corticosteroid therapy, macular photocoagulation, and vitrectomy. The baseline and final BCVA, and the number and timing of interventions were recorded. Eyes were classified according to the year in which intervention was initiated. Results: Over a 2-year period, BCVA improved annually, finally reaching 7 letters. The proportion of eyes in which good vision was maintained (BCVA >20/40) increased to 73.3% in the latest period. The administration of anti-VEGF therapy remained stable, accounting for approximately 90% of eyes. Notably, the proportion of eyes receiving anti-VEGF drugs as first-line treatment increased dramatically to approximately 80%. Conclusion: Anti-VEGF therapy has become the first-line treatment since the approval of anti-VEGF drugs for DME. These findings reflect the evolution of DME treatment and highlight the superiority of anti-VEGF therapy and its increased uptake over time.